U.S. Personal Products Stock News

Krystal Biotech received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for KB707 in advanced non small cell lung cancer. The company reported progress across its gene therapy pipeline, including pivotal ophthalmology trials with data expected next year. These updates extend Krystal Biotech’s focus beyond rare skin diseases into larger indications such as lung cancer. For investors following Krystal Biotech, ticker NasdaqGS:KRYS, the RMAT news comes with the shares at $274.59...

Earlier this month, Analog Devices reported first-quarter fiscal 2026 results showing sales of US$3.16 billion and net income of US$830.83 million, alongside new guidance calling for roughly US$3.5 billion in second-quarter revenue and reported EPS around US$2.19. The company also lifted its quarterly dividend by 11% to US$1.10 per share and continued share repurchases, underscoring management’s confidence in cash generation and long-term demand across industrial, communications, and...

Graco (NYSE:GGG) board member Brett C. Carter has resigned from the board. Carter cited personal and professional commitments for his departure, with no disagreements related to Graco reported. His resignation affects board roles tied to key areas such as audit and compensation oversight. Graco, known for its equipment for fluid handling across industrial and commercial applications, operates in a part of the market that can be influenced by broader trends in manufacturing, construction,...

If you are wondering whether Voyager Technologies is attractively priced or just a value trap, this article walks through what the numbers are actually saying about the stock. The share price recently closed at US$26.82, with a 3% return over the past week, a 27.7% decline over the last 30 days, and a 3.5% decline year to date, which may signal shifting views on its potential and risk. Recent news coverage around Voyager Technologies has focused on its position in the capital goods space and...

If you are wondering whether Reddit's current share price lines up with its underlying value, you are not alone, and that is exactly what this article will unpack for you. Reddit recently closed at US$142.46, with a 2% gain over the last 7 days but declines of 34.9% over 30 days and 41.1% year to date, which may signal changing expectations and risk perceptions around the stock. Recent headlines have focused on Reddit's role in online communities and its position among US media and social...

Cirrus Logic executives, including EVP Justin E. Dougherty, recently reported significant insider share sales. The transactions followed the company posting record net income and strong earnings per share. These clustered insider moves come as Cirrus Logic (NasdaqGS:CRUS) trades around $142.95. Cirrus Logic (NasdaqGS:CRUS) is in focus after record net income and strong earnings per share were followed by insider selling from multiple senior leaders. The share price sits at about $142.95,...

If you are wondering whether Acadia Healthcare Company is attractively priced or still a value trap after a tough run, this breakdown is designed to give you a clear view of where the stock stands today. The shares last closed at US$17.38, with returns of 3.6% over 7 days, 14.1% over 30 days, 21.6% year to date, but a 57.3% decline over 1 year and a 78.4% decline over 3 years. This raises questions about how the current price lines up with underlying value. Recent news coverage has largely...

GE Vernova (NYSE:GEV) is entering what management describes as a new growth supercycle, supported by surging power demand from AI data centers. The company reports a 65% jump in orders and aims to expand an already large $150b backlog. Recent capital allocation moves include doubling the dividend and authorizing a sizable share buyback program. GE Vernova comes into this shift with strong recent share performance, with the stock up 26.4% over the past month and 163.9% over the past year,...

Recent share performance and business context Copart (CPRT) shares have pulled back recently, with a 1 day return of around a 3% decline, and weaker performance over the past week, month, and past 3 months drawing fresh attention from investors. The company runs online auctions and vehicle remarketing services across multiple countries, processing and selling vehicles over the internet for dismantlers, rebuilders, dealers, exporters, and the public. See our latest analysis for Copart. At a...

Credo Technology Group Holding’s PCIe 6.0-capable Toucan retimer has achieved PCI-SIG compliance, confirming it meets industry standards for the latest PCIe 6.0 technology. The company also introduced new connectivity products, including the Blue Heron 224G AI scale-up retimer and additional PCIe 6.0-capable devices aimed at AI and data center workloads. These launches focus on higher bandwidth and reliability for customers building AI clusters and advanced data center infrastructure. Credo...

If you are wondering whether Centuri Holdings' share price still reflects good value, or if the recent excitement has already been priced in, this article will walk you through what the numbers indicate about the stock. The shares last closed at US$31.24, with returns of 0.7% over 7 days, 10.0% over 30 days, 21.0% year to date and 72.1% over the past year. This has naturally raised questions about how the current price compares with underlying value. Recent news flow around Centuri Holdings...

If you are wondering whether Baxter International's share price reflects its underlying value, this article will walk you through what the current market price might be implying. The stock last closed at US$21.26, with returns of 7.4% over 7 days, 7.2% over 30 days and 9.0% year to date, set against a 38.3% decline over 1 year, 42.8% over 3 years and 69.7% over 5 years. Recent news flow around Baxter International has focused on the company's long term repositioning and ongoing portfolio...

What Proto Labs investors can glean from recent performance Proto Labs (PRLB) has moved sharply over the past year, with the stock returning 57.3% and showing double digit gains over the past month and past 3 months, catching the attention of many investors. Alongside that share price performance, the company reports annual revenue of US$533.1 million and net income of US$21.2 million, with recent annual revenue and net income growth rates of 6.4% and 24.4% respectively. See our latest...

If you are looking at O'Reilly Automotive and wondering whether the current share price still offers value, this article will walk through what the numbers actually say. The stock closed at US$95.35, with returns of 1.4% decline over the last 7 days, 3.9% decline over 30 days, a 5.5% gain year to date, 8.8% over 1 year, 69.1% over 3 years and 217.0% over 5 years. This raises fair questions about how much of the story might already be priced in. Recent coverage has focused on O'Reilly...

If you are looking at Southern and wondering whether the current share price lines up with its underlying value, you are not alone. Southern's share price recently closed at US$95.18, with returns of 0.2% over 7 days, 8.7% over 30 days, 9.2% year to date, 10.6% over 1 year, 64.5% over 3 years and 98.5% over 5 years shaping how investors are thinking about its potential and risk. Recent coverage of Southern has focused on its position in the US utilities sector and the market's ongoing...

Investor focus on Agilent Technologies (A) is picking up as the life sciences tools company heads into its upcoming earnings report, with attention also on fresh FDA approval for its PD-L1 IHC 22C3 pharmDx companion diagnostic. See our latest analysis for Agilent Technologies. At a share price of $124.20, Agilent’s recent 1 day share price gain contrasts with a 30 day share price return of 8.03% decline and a 1 year total shareholder return of 7.45% decline. This suggests momentum has...

Vanda Pharmaceuticals recently received U.S. FDA approval for BYSANTI (milsaperidone) tablets, a new atypical antipsychotic for acute manic or mixed episodes in bipolar I disorder and for schizophrenia in adults, with U.S. commercial launch targeted for the third quarter of 2026 and marketing protection expected into 2044. BYSANTI’s status as a new chemical entity that rapidly converts to iloperidone, aligning with Fanapt’s established safety profile while offering dual active molecules,...

If you are wondering whether Trade Desk is starting to look attractively priced or still expensive, the recent share moves give you a lot to think about. The stock last closed at US$24.17, with returns of a 6.4% decline over 7 days, 33.9% decline over 30 days, 35.9% decline year to date and 67.4% decline over 1 year. The 3 year and 5 year returns sit at a 56.1% decline and 71.0% decline respectively. Recent news coverage has focused on Trade Desk's role in the broader digital advertising...

Regions Financial (RF) has drawn fresh attention after major firms including J.P. Morgan and UBS raised their views on the stock, even as recent quarterly results fell short of some market estimates. See our latest analysis for Regions Financial. At a share price of US$28.71, Regions Financial has recently seen a 12.94% 90 day share price return and a 27.80% 1 year total shareholder return, suggesting near term momentum alongside stronger multi year gains as investors reassess earnings...

Zymeworks recently reported positive Phase 3 results for zanidatamab in first-line HER2-positive gastroesophageal cancer, alongside year-end 2025 financials showing solid cash reserves and an existing US$125 million share repurchase authorization, while Redmile Group disclosed about US$70 million of share sales. Together, the encouraging late-stage clinical data, strengthened balance sheet, and ongoing buyback authorization highlight a shift toward reinforcing the company’s royalty-focused,...

Ferrari (NYSE:RACE) has launched a multi year share buyback program totaling €3.5b. The company has started the first tranche of purchases, beginning the execution phase of this plan. The buyback framework is designed to run over several years, signaling active capital return to shareholders. For investors, this move comes from a company known for its high end sports cars, racing heritage, and tightly controlled brand. A multi year buyback of this size reflects a balance sheet that can...

What Zurn Elkay Water Solutions’ Recent Performance Signals for Investors Zurn Elkay Water Solutions (ZWS) has drawn fresh attention after a period of mixed short term returns, with the stock showing a 1 day decline, a small weekly pullback, yet gains over the past month and past 3 months. At a last close of US$49.93, the company sits on a 1 year total return of 44.56%. Longer horizons show very large gains over 3 and 5 years, alongside annual revenue of US$1.70b and net income of...

Earlier in February 2026, Lyft reported full-year 2025 results showing US$6,316.26 million in sales and US$2,844.01 million in net income, alongside a new US$1,000 million share repurchase authorization and a US$337.72 million employee stock-related shelf registration for Class A common stock. These moves, combined with management’s focus on market share recovery, pricing discipline and operational efficiencies, highlight Lyft’s effort to balance employee incentives, capital returns and...

In February 2026, iRhythm Holdings reported Q4 2025 results showing sales of US$208.89 million and a return to quarterly profitability, while full-year 2025 revenue reached US$747.14 million with a reduced annual net loss. The company also issued 2026 revenue guidance of US$870 million to US$880 million and highlighted expansion plans, AI-enabled product development, and international growth initiatives as it works to improve efficiency and broaden its cardiac monitoring platform. We’ll now...